Zacks Investment Research on MSN5h
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases ProgramNurix Therapeutics NRIX shares rose 8.7% on Wednesday after the company announced that Sanofi SNY has in-licensed exclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback